Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan  by Chella, Naveen et al.
Chinese Pharmaceutical AssociationInstitute of Materia Medica, Chinese Academy of Medical Sciences
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2012;2(5):502–5082211-3835 & 2012 In
hosting by Elsevier B
http://dx.doi.org/10.1
nCorresponding au
E-mail address:
Peer review underwww.elsevier.com/locate/apsb
www.sciencedirect.comORIGINAL ARTICLE
Use of the liquisolid compact technique for improvement of
the dissolution rate of valsartanChella Naveena,c, Nalini Shastria, Rama Rao Tadikondab,naNational Institute of Pharmaceutical Education and Research, Hyderabad 500037, India
bBlue Birds College of Pharmacy, Hanamkonda 506001, India
cDepartment of Pharmacy, Acharya Nagarjuna University, Guntur 522510, India
Received 8 March 2012; revised 29 March 2012; accepted 18 May 2012KEY WORDS
Liquisolid compact;
Valsartan;
Dissolution;
Poorly soluble drugstitute of Materia M
.V. All rights rese
016/j.apsb.2012.07
thor. Tel.: þ91 994
tadikondarao@yah
responsibility of InAbstract The aim of this study was to improve the dissolution rate of the poorly soluble drug valsartan
by delivering the drug as a liquisolid compact. Liquisolid compacts were prepared using propylene glycol
as solvent, Avicel PH102 as carrier, and Aerosil 200 as the coating material. The crystallinity of the newly
formulated drug and the interaction between excipients was examined by X-ray powder diffraction and
Fourier-transform infrared spectroscopy, respectively. The dissolution studies for the liquisolid formula-
tion and the marketed product were carried out at different pH values. The results showed no change in
the crystallinity of the drug and no interaction between excipients. The dissolution efﬁciency of valsartan
at 15 min was increased from 4.02% for plain drug and 13.58% for marketed product to 29.47% for the
liquisolid formulation. The increase in the dissolution rate was also found to be signiﬁcant compared to
the marketed product at lower pH values, simulating the gastric environment where valsartan is largely
absorbed. The liquisolid technique appears to be a promising approach for improving the dissolution of
poorly soluble drugs like valsartan.
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The oral route is the most preferred means of drug adminis-
tration due to the ease, high patient compliance, and low cost
of production. The drug must be presented in solution form
for absorption through gastrointestinal tract (GIT) when
given orally. In the case of poorly soluble drugs, dissolution
is the rate-limiting step in absorption process1. Generally,
compounds with aqueous solubility lower than 100 mg/mL
show dissolution-limited absorption2 and erratic and/or incom-
plete absorption from the gastrointestinal tract of animals and
humans1. Advancements in the ﬁelds of biotechnology and drug
discovery have led to the discovery of increasingly large number
of active molecules. However, 40% of all newly developed
drugs are poorly soluble or insoluble in water, leading to
ineffective absorption and therapeutic failure3.
Various techniques are reported to improve the dissolution
of poorly soluble drugs, including solid dispersions4, crystal
engineering5, ball milling6, complexation7, self-emulsifying drug
delivery systems8 and the use of mesoporous silica carriers9.
Recently, the liquisolid technique10 has shown promise for
improved dissolution.
The concept of liquisolid tablets was developed from
powdered solution technology that can be used to formulate
liquid medication11. A liquisolid system is deﬁned as dry, non-
adherent, free-ﬂowing and compressible powder mixtures
converted from liquid drugs, drug suspensions or drug solu-
tions in nonvolatile solvents with selected carriers and coating
materials12. In this technique, the drug is dissolved in a non-
volatile liquid and converted to dry, free ﬂowing and com-
pressible solid using carrier and coat materials10. Since non-
volatile solvents are used to prepare the drug solution/
suspension, the liquid is not evaporated and the drug is
carried in a liquid system and is dispersed throughout the
ﬁnal product. A mathematical model by Spireas and Bolton10
was used to calculate the required quantities of carrier and
coating material to be added to produce acceptable ﬂow and
compressibility. The liquisolid technique has shown promising
results for the drugs like carbamazepine12, atorvastatin cal-
cium13 and fenoﬁbrate14.
Valsartan is an antihypertensive agent which selectively
inhibits the type 1 angiotensin II receptor. Valsartan is poorly
soluble and the aqueous solubility was reported to be less than
1 mg/mL. The drug is rapidly absorbed following oral admin-
istration with a bioavailability of about 23%15. Valsartan is
weakly acidic so it is poorly soluble in the acidic environment
where its absorption window exists16. It is necessary to
improve the dissolution rate in stomach so as to improve
the bioavailability of the drug. Various techniques, such as
orodispersible tablet17, self emulsifying drug delivery system18
and solid dispersions19, were reported previously. The present
study was aimed to improve the dissolution of valsartan using
liquisolid compaction technique.2. Materials and methods
2.1. Materials
Valsartan was kindly gifted by Aurobindo Pharmaceuticals
(Hyderabad, India). Aerosil 200 and Avicel PH102 were gift
samples from AVL Pharmaceuticals (Hyderabad, India) andSignet Chemicals Corporation (Mumbai, India). Croscarmellose
sodium, tween 20, tween 80, polyethylene glycol (PEG200,
PEG400 and PEG600), propylene glycol (PG), sodium hydro-
xide, potassium dihydrogen orthophosphate were purchased
from Sd Fine-Chem Ltd. (Mumbai, India). Lactose and dical-
cium phosphate (DCP) were purchased from Nehal traders
(Hyderabad, India). All other chemicals, reagents and solutions
used were of analytical grade. Marketed product Valzaar 40 mg
(Torrent Pharmaceutical Ltd., Ahmadabad) was procured from
local pharmacy.2.2. Solubility studies
To select the best non-volatile solvent to dissolve valsartan,
solubility studies of valsartan were carried out in six different
non-volatile solvents, i.e., PEG200, PEG400, PEG600, tween
20, tween 80 and propylene glycol. Saturated solutions were
prepared by adding excess drug to the vehicles and shaking on
the incubator shaker (JEIOTECH, Korea) for 48 h at
2571 1C. After shaking, the solutions were ﬁltered through
a 0.45 mm Millipore ﬁlter, diluted with distilled water and
analyzed by UV-spectrophotometer (JASCO V-650, Japan) at
a wavelength of 250 nm against blank (blank sample con-
tained the same concentration of speciﬁc solvent without
drug). Six determinations were carried out for each sample
and the mean values along with standard deviations were
reported.2.3. Binding capacity of adsorbents for the solvents
Binding capacity is deﬁned as the capacity of powder
excipients to hold liquid without change in their ﬂow properties.
It was determined by the following simple method. A constant
weight of 5 g of different powder excipients (Avicel PH102,
lactose and dicalcium phosphate) were put into a mortar
and propylene glycol was added in increments of 0.01 mL.
The mixture was triturated after each addition to help distribu-
tion of the liquid throughout the powder particles. Addition
of liquid was continued until lumps appeared in the powder
mixture20.2.4. Calculation of load factor
In a liquisolid system, the amount of liquid retained by the
carrier and coating materials depends on the excipient ratio
(R) while maintaining acceptable ﬂow and compression
properties. The excipient ratio R (R¼Q/q) of a powder is
deﬁned as the ratio between the weights of carrier (Q) and
coating materials (q) present in the formulation21. Preparation
of a liquisolid system with an acceptable ﬂow rate and
compressibility is possible when a maximum amount of
retained liquid of the carrier material is not exceeded. This
characteristic amount of liquid is termed as liquid load factor
(Lf). The liquid load factor (Lf) is deﬁned as the weight ratio of
the liquid medication (W) and carrier powder (Q) in the
system (i.e., Lf¼W/Q)22. To calculate the loading factor,
propylene glycol (liquid medication without drug) was added
to 10 g carrier material and blended for 1 min. The above
procedure was repeated until a powder with acceptable ﬂow
rate was obtained.
Table 1 Solubility of valsartan in different solvents
(all values are mean7SD; n¼3).
Solvent Solubility (mg/mL)
Tween 20 69.7372.38
Tween 80 76.5772.67
PEG 200 65.4171.23
PEG 400 69.5771.98
PEG 600 83.9172.89
PG 109.2373.21
PEG, polyethylene glycol; PG, propylene glycol.
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Fixed funnel and the free-standing cone method were
employed to measure the angle of repose. A funnel was
secured with its tip at a given height (H) above a graph paper
placed on a ﬂat horizontal surface. The powders were carefully
poured through the funnel until the apex of the conical pile
just touches the tip of the funnel. The mean radius (r) of the
base of the conical pile was determined and the tangent of
angle of repose was given by Tan a¼H/r, where a is the angle
of repose23.
2.6. X-ray powder diffraction (XRD)
XRD patterns were studied using Philips PW 3710 X-ray
diffractometer. Samples were exposed to 1.540 A˚ Cu radiation
wavelength and analyzed over the 2y range of 2–801. XRD
patterns were determined for valsartan, formulation without
drug (blank formulation) and liquisolid system with drug.
From the literature, it was evident that Aerosil 200 was a non-
gritty amorphous powder22; and from the blank formulation,
Avicel PH102 spectra can be evaluated.
2.7. Preparation of conventional tablet and liquisolid
compacts
The liquisolid compacts were prepared according to the
method described by Spireas and Bolton10. Valsartan was
dissolved in propylene glycol which is used as a liquid vehicle
to prepare the drug solution. The mixture of carrier-coating
materials (Avicel PH102, lactose or DCP as the carrier powder
and Aerosil 200 as the coating material) was added to the
liquid medication and blended in a porcelain mortar avoiding
excessive trituration and particle size reduction. The mixing
was done in three stages: ﬁrst, the system was mixed slowly to
allow uniform distribution of liquid medication; second, the
mixture was spread as a uniform layer on the surface of the
mortar and left standing for a few minutes; ﬁnally, 10% of
disintegrant (croscarmellose sodium) was added to the powder
and mixed thoroughly. The ﬁnal mixture was compressed into
tablets.
2.8. Evaluation of liquisolid tablets
The prepared liquisolid tablets were evaluated for hardness,
friability and disintegration time. Hardness was determined by
the Pﬁzer hardness tester and friability by a digital tablet
friability tester. The disintegration time was measured using a
USP disintegration tester (Electrolab). All the studies were
done in triplicate.
2.9. Dissolution studies
Dissolution studies were performed for liquisolid compacts,
plain drug and marketed product (Valzaar-40 mg). The USP
paddle method was used for all in vitro dissolution studies.
The dissolution was carried out at different pH values using
different media, i.e., 0.1 M HCl (pH 1.2), 0.001 M HCl (pH
3.0), acetate buffer (pH 4.5) and phosphate buffer (pH 6.8).
The stirring rate was 5071 rpm. The amount of valsartan was
40 mg in all formulations. The dosage forms were placed in1 L dissolution medium and maintained at 3770.5 1C. At
appropriate intervals (5, 10, 15, 20, 25, 30 and 45 min), 5 mL
of samples were taken and ﬁltered through a 0.45 mm ﬁlter.
The samples were analyzed at 250 nm by UV–visible spectro-
scopy. The mean value of six determinations was used to
calculate the drug release from each formulation. For the
comparison of dissolution data in different media for each
formulation, percentages of drug dissolved at 10 min (Q10 min),
30 min (Q30 min), mean dissolution time (MDT) and dissolu-
tion efﬁciency (DE) at 15 min were calculated24.
2.10. FTIR spectroscopy
FTIR spectra of drug, Avicel PH102, Aerosil, liquisolid
placebo and liquisolid tablet were obtained. About 5 mg of
sample was mixed thoroughly with 100 mg potassium bromide
IR powder and compacted under vacuum at a pressure of
about 12,000 psi for 3 min. The resultant disk was mounted in
a suitable holder in Perkin Elmer IR spectrophotometer and
the IR spectrum was recorded from 4000 cm1 to 625 cm1 in
a scan time of 12 min. The resultant spectra were compared
for any spectral changes.3. Results and discussion
Valsartan is given as an immediate release tablet and has an
absorption window in the upper gastrointestinal tract. Hence,
the objective of this work was to improve the dissolution of
valsartan at pH values that simulate gastric conditions so as to
improve gastric absorption.
3.1. Vehicle selection
The solubility of valsartan was determined in a number of
solvents and is presented in Table 1. Drug solubility in a non-
volatile vehicle is the most important aspect in liquisolid
systems. The solubility of the drug contributes to molecular
dispersion in a non-volatile solvent which will improve the
dissolution rate. Based on the solubility data, PG was selected
as the vehicle for valsartan.
3.2. Liquisolid compacts
Spireas et al.21 suggested that particles with high absorption
properties due to a porous surface should be used as the
carrier material, such as cellulose, starch and lactose.
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in decreased powder ﬂowability. The coating material is
required to cover the surface, and further, maintain the
powder ﬂowability11. Accordingly, the coating material should
be a very ﬁne and highly adsorptive silica powder. From the
preliminary binding capacity experiments conducted with
different excipients, Avicel PH102 was selected as carrier
and Aerosil 200 as the coat material. Valsartan liquisolid
tablets (F1–F12) were prepared with different excipient ratios
(R) using PG as vehicle (Table 2). The appropriate amounts of
the carrier and coating material were derived from their liquidTable 2 Formulations of liquisolid compacts (LSC).
Formulation
Drug conc. in
PG (% w/w)
Ra Lf
b
F1 15 5 0.665
F2 10 0.532
F3 20 0.443
F4 20 5 0.666
F5 10 0.5
F6 20 0.4
F7 40 5 0.333
F8 10 0.25
F9 20 0.20
F10 60 5 0.22
F11 10 0.24
F12 20 0.264
aExcipient ratio, R¼Q/q. Q, weight of carrier; q, weight of coating
bLiquid load factor, Lf¼W/Q. W, weight of liquid medication.
cQ¼W/Lf.
dq¼Q/R.
Figure 1 FTIR spectra of pure drug and different excipients. (a) Aer
(e) LSC formulation (F11).load factors. The Lf was greater than 0.25 for formulations
F1–F8 and F12 (Table 2), showing poor ﬂowability and
compressibility12.
The angle of repose is a result of internal frictional forces of
the particles. The angle of repose will be high if the particles
are cohesive. Angles of reposer301 indicate free ﬂow while
anglesZ401 indicate poor ﬂow23. Powder formulations with angles
of repose greater than 401 were not acceptable (formulations
F1–F8 and F12). Formulations F9, F10 and F11 showed 281, 351
and 321, respectively. Formulation F9 showed good ﬂowability
but required a higher amount of carrier material which increasedAvicel PH102c Aerosil 200d
Formulation
weight (mg)
400 80 580
500 50 650
600 30 750
300 60 460
400 40 530
500 25 620
300 60 450
400 40 530
500 25 610
300 60 440
275 27.5 370
250 12.5 340
material.
osil 200, (b) Avicel PH102, (c) valsartan, (d) physical mixture and
Figure 2 XRD spectra of different excipients and formulations.
(i) Valsartan, (ii) LSC formulation F11 and (iii) LSC formulation
without drug.
Figure 3 Dissolution proﬁle of marketed product (MP) and test pro
0.1 M hydrochloric acid (pH 1.2), (b) dissolution proﬁle in 0.001 M h
(pH 4.5), and (d) dissolution proﬁle in phosphate buffer (pH 6.8). All
Chella Naveen et al.506the tablet size to 610 mg. Hence formulation F10 and F11 were
selected for compression.
The tablets should have sufﬁcient hardness to resist the
breakage during handling, and at the same time, it should
disintegrate after swallowing. Formulation F11 showed good
compressibility with an acceptable hardness (3–4 kg). Some
liquid was squeezed out from formulation F10 at the same
hardness. This could be attributed to a lesser quantity of coat
material in F10, which is not sufﬁcient to adsorb liquid on its
surface and maintain sufﬁcient ﬂowability and compressibility.
Based on this study, F11 was selected for further evaluation.
Formulation F11 shows satisfactory ﬂowability (angle of
repose 321), hardness (3.5 kg) and disintegration time (2 min)
at a total tablet weight of 370 mg.3.3. FTIR and XRD
Samples of valsartan, Aerosol 200, Avicel PH102, as physical
mixtures and liquid solid formulations were subjected to FTIR
spectroscopic analysis and their spectra are shown in Fig. 1.
Fig. 2 shows XRD diffraction spectra of valsartan, formula-
tion without drug and ﬁnal liquisolid formulation F11.
The IR spectrum of valsartan (Fig. 1c) exhibits character-
istic peaks at 3300 cm1 (N–H functional group), 2963 cm1
(C–H group stretching vibration), 1734 cm1 (carboxyl carbo-
nyl), 1603 cm1 (amide carbonyl group). The peak at
1458 cm1 indicates the presence of CQC aromatic group.
Appearance of these peaks in the physical mixture andduct (TP) in different dissolution media. (a) Dissolution proﬁle in
ydrochloric acid (pH 3.0), (c) dissolution proﬁle in acetate buffer
values are mean7SD, n¼6; Po0.05 vs. marketed formulations.
Table 3 Dissolution parameters of marketed and test products.
Dissolution media Q10 min (%) Q30 min (%) DE (%) MDT (min)
MP TP MP TP MP TP MP TP
0.1 M HCl (pH 1.2) 17.59(72.61) 40.6(72.44) 31.04(72.2) 60.20(74.43) 13.58(71.43) 29.47(71.38) 36.24(73.81) 26.49(71.93)
0.001 M HCl (pH 3.0) 23.34(72.27) 70.14(70.49) 37.92(73.57) 86.37 (71.66) 18.33(71.51) 50.91(70.76) 29.94(72.22) 14.15(72.55)
Acetate buffer (pH 4.5) 71.06(79.34) 87.80(73.94) 87.40(74.76) 103.99(76.33) 50.95(74.69) 68.13(72.50) 14.27(73.40) 5.68(70.90)
Phosphate buffer
(pH 6.8)
88.68(77.92) 90.07(74.16) 94.79(75.79) 100.09(72.08) 68.58(75.08) 72.16(72.86) 5.14(70.93) 3.81(70.87)
MP, marketed product; TP, test product. DE, dissolution efﬁciency; MDT, mean dissolution time. Data are expressed as mean (7SD).
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action between the drug and excipients.
XRD spectra of valsartan powder did not show any distinct
peak in Fig. 2i, indicating that the drug may be in amorphous
form or the particle size was very small (less than 0.1 mm)25.
From the results shown in Fig. 2, it is evident that the peaks in
the physical mixture and ﬁnal formulation were characteristic
of Avicel PH102. It can be concluded that the increase in
dissolution was not due to a change in crystallinity, but rather
to increased wetting.
3.4. Dissolution improvement
Dissolution studies for the liquisolid formulation (F11) and
marketed product (valzar 40 mg) were conducted in different
media as noted in Section 2.9, and the percent drug release at
different time intervals is shown in Fig. 3. MDT, Q10 min, Q30 min
and DE of the liquisolid formulation and marketed product were
calculated in different media and reported in Table 3. DE at
15 min for the plain drug was found to be 4.02% and 7.52% in
0.1 M HCl and 0.001M HCl, respectively.
From the dissolution data it was observed that more than
90% of the drug was released from both liquisolid and
marketed formulation in 30 min in phosphate buffer (pH
6.8) and in 60 min in acetate buffer (pH 4.5, data not shown).
So dissolution was carried out at different pH values (1.2, 3.0,
4.5 and 6.8) to differentiate the media and to compare
the dissolution proﬁles. The percentage of drug dissolved at
10 and 30 min (Q10 min and Q30 min) of LSC formulation (F11)
was greater than that of marketed product in all dissolution
media. The dissolution rate was signiﬁcantly increased
(Po0.05) at lower pH (pH 1.2 and 3.0) and no signiﬁcant
difference was found at higher pH (pH 4.5 and 6.8) due to the
high solubility of the drug at higher pH. This result was also
supported by further analysis of dissolution data using MDT
and DE at 15 min. The DE of valsartan was increased seven-
fold compared to plain drug and doubled when compared with
marketed product. DE values also increased with an increase
in pH due to the high solubility of the drug at higher pH
values. MDT values of the test product were low at all pH,
indicating faster dissolution than marketed dosage form.
The increased dissolution of the liquisolid formulation is
probably due to the drug presenting in a solubilised state in the
formulation, which contributes to increased wetting properties,
thereby enhancing the dissolution rate. Similarly, the drug will be
presented in a state of molecular dispersion as the formulation
disintegrates in dissolution media. This will increase the effective
surface area of the particles available for dissolution.4. Conclusions
The liquisolid technique was found to be a promising
approach for improving the dissolution of a poorly soluble
drug like valsartan. The dissolution of valsartan was signiﬁ-
cantly increased in liquisolid formulation compared to the
marketed product. XRD and IR spectra indicate that there
was no change in the crystalline state of the drug and no
interactions between the drug and excipients. The increased
dissolution rate may be due to increased wetting and increased
surface area of the particles.
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